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Abstract 
CD95 (also known as Fas) is a death receptor that 
belongs to the TNF-receptor superfamily. Expressed 
at the cell surface as a homotrimer, this receptor 
implements both apoptotic and non-apoptotic 
signalling pathways. While the apoptotic signalling 
pathway is involved in tumor surveillance, 
peripheral tolerance and immune homeostasis 
(Strasser et al., 2009), its non-apoptotic cues seem to 
promote oncogenesis (Chen et al., 2010; Hoogwater 
et al., 2010; Kleber et al., 2010; Malleter et al., 2013; 
Steller et al., 2011). 
Keywords: CD95, Fas, apoptosis, inflammation, 
auto-immunity, metastasis 
Identity 
Other names: ALPS1A, APO-1, APT1, CD95, 
FAS1, FASTM, TNFRSF6 
HGNC (Hugo): FAS 
Location: 10q23.31 
Note: Based on published GeneBank sequences, this 
gene has seven potential transcription start sites 
located at 88 969 796, 88 990 531, 88 990 657 and 
90 750 288 bp from pter. 
Gene localisation: CD95 gene spans approximately 25 kb on human chromosome 10. 
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Gene annotation is APT1. 
Description 
CD95 gene is composed of 9 exons. 
Transcription 
According to Ensembl, the gene has 18 transcripts 
(splice variants). Among them, three transcripts 
encode for proteins (represented in the diagram). 
Variant 1 encodes for the longest protein of 335 aa. 
Variant 2 encodes for a CD95 protein lacking 
transmembrane region (exon 6) and thus 
corresponding to a soluble receptor. Variant 3 
contains a distinct and shorter c-terminus compare to 
variant 1 and encodes for a protein of 220 aa. 
Pseudogene 
No known pseudogenes. 
Protein 
Note 
Type I transmembrane protein. 
Description 
CD95 displays two different numberings. While 
some researchers start to count from the first 
translated amino acid after methionine (335 aa), 
others start at the first amino acid after signal peptide 
(319 aa) (Itoh et al., 1991). CD95 contains three 
cysteine-rich domains (CRDs). CRD2 and the upper 
part of CRD3 interact with CD95L (Schneider et al., 
1997). CD95 is expressed at the plasma membrane 
as a pre-associated homotrimer (Siegel et al., 2000) 
because of homotypic interactions occurring 
between its pre-ligand assembly domains (PLAD) 
(amino acids 43 to 66 (Edmond et al., 2014), count 
starts after signal peptide).  
The intracellular region of CD95 encompasses an 
87-amino-acid-long stretch designated the death 
domain (DD) whose structure consists of six 
amphipathic α-helices arranged anti-parallel to one 
another (Huang et al., 1997). The 15 last amino acids 
of CD95 exert an inhibitory action on the CD95-
mediated apoptotic signal due to the recruitment of 
the phosphatase FAP1 (Yanagisawa et al., 1997). 
 
CD95 is a 335 amino acids type 1 transmembrane glycoprotein. Signal peptide corresponds to amino acid 1 to 16 (Itoh et al., 
1991). The PLAD (pre-ligand assembly domain) and the CRDs (cysteine-rich domain) are encoded by exon 2 to 5. Exon 6 
encompasses the transmembrane domain (TM), and the CD95 intracellular region consists in exons 7 to 9. The FAS DD is 
encoded by exon 9. 
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The molecular weight of CD95 varies between 40 to 50 kDa due to different post-translational modifications: glycosylation 
(Shatnyeva et al., 2011; Keppler et al., 1999), nitrosylation (Leon-Bollotte et al., 2011), S-glutathionylation (Anathy et al., 2009) 
and palmitoylation (Chakrabandhu et al., 2007; Feig et al., 2007). 
 
Expression 
CD95 is ubiquitously expressed in human body. 
Localisation 
CD95 is mainly found at cell surface. CD95 is 
retained internalized in cells through a FAP-1-driven 
mechanism, while its translocation to the cell surface 
relies on dynamin-2 (Ivanov et al., 2003; Ivanov et 
al., 2006). 
Function 
CD95 contributes to immune homeostasis, 
elimination of transformed and infected cells, and 
plays a pivotal role in peripheral tolerance. 
CD95/CD95L pair is also responsible for preventing 
inflammation in certain tissues designated immune 
privileged sites, such as eyes and testis. More 
recently, CD95 has been shown to promote 
carcinogenesis ((Chen et al., 2010; Hoogwater et al., 
2010; Kleber et al., 2010; Malleter et al., 2013; O' 
Reilly et al., 2009). 
Upon binding of membrane-bound CD95L to CD95, 
CD95-DD recruits the adaptor molecule Fas-
associated death domain protein (FADD) and 
caspase-8, leading to caspase activation and 
apoptosis (Kischkel et al., 1995). The complex 
CD95/FADD/Caspase-8 is called death-inducing 
signalling complex (DISC) (Kischkel et al., 1995). 
DISC formation is regulated by several molecular 
mechanisms including c-FLIP (FLICE-like-
inhibitory-protein) (Irmler et al., 1997), FAP-1 (Fas 
associated phosphatase 1) (Sato et al., 1995) and 
PED-PEA15 (Condorelli et al., 1999). 
Cells can be divided in two groups with regard to the 
magnitude of DISC formation, and the role played 
by the mitochondrion in this pathway (Scaffidi et al., 
1998). In type I cells, DISC formation occurs rapidly 
and efficiently, resulting in the release of a large 
amount of activated caspase-8 in the cytosol. 
Whereas, type II cells have difficulties forming this 
complex, and the amount of active caspase-8 is 
insufficient to directly activate the effector caspase-
3 and caspase-7 (Scaffidi et al., 1998). The low level 
of activated caspase-8 in type II cells is sufficient to 
cleave BID, a BH3-only protein, which links the 
death receptor to the apoptotic activity of 
mitochondria. Indeed, caspase-8-driven BID 
truncation generates tBID, which translocates to 
mitochondria, and triggers the release of pro-
apoptotic factors (Yin, 2000; Yin et al., 1999). Type 
II cells are addicted to this latter signal because they 
contain higher levels of the caspase-3 inhibitor XIAP 
than type I cells (Jost et al., 2009). To summarize, 
DISC formation and IAP amount are two cellular 
markers that allow a clear discrimination between 
type I and type II cells. 
CD95 engagement also induces non-apoptotic 
signalling pathways promoting cell motility, 
invasiveness (Hoogwater et al., 2010; Kleber et al., 
2010; Malleter et al., 2013; Steller et al., 2011; 
Barnhart et al., 2004), inflammation (O' Reilly et al., 
2009; Audo et al., 2014; Letellier et al., 2010; Tauzin 
et al., 2011) and organ regeneration (Desbarats et al., 
2003; Desbarats and Newell, 2000). Indeed, CD95 
can implement NFκB (O' Reilly et al., 2009; 
Barnhart et al., 2004; Wajant et al., 1998), 
phosphatidylinositol 3-kinase (PI3K) (Kleber et al., 
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2008;Tauzin et al., 2011) or MAPK signaling 
pathways (Hoogwater et al., 2010; Desbarats et al., 
2003). CD95 has also been reported to play a pivotal 
role in T cell activation (Akimzhanov et al., 2010; 
Alderson et al., 1993). 
Of note, while interaction of transmembrane CD95L 
with CD95 triggers cell death, its metalloprotease-
cleaved counterpart (cl-CD95L) does not form 
DISC, but induces the formation of an atypical 
complex designated motility-inducing signalling 
complex (MISC)5. 
Homology 
The CD95-mediated apoptotic system is conserved 
among all mammals. The most primitive 
invertebrate TNF/TNFR pair has been reported in 
the fruit fly Drosophila melangastor (Kauppila et al., 
2003; Moreno et al., 2002; Collette et al., 2003). 
However, a more recent study highlighted that 
TNFSF and TNFRSF members are conserved in 
more ancient invertebrates such as Cnidaria (Quistad 
et al., 2014). Moreover, comparison of coral 
TNFSF/TNFRSF members with proteins from 




Most of the mutations are gathered in exons 8 and 9 
encoding the CD95 intracellular region. Malignant 
tumor cells and ALPS type Ia cells harboring a 
heterozygous mutation inside the CD95-DD, exhibit 
resistance to the CD95-mediated apoptotic signal, 
but remain able to elicit non-apoptotic signal such 
NFkB, MAPK, and PI3K (Legembre et al., 2004). 
Tree "hot-spots" of mutation (arginine in position 
234, aspartic acid in position 244 and valine in 
position 251) have been identified and implicated in 
the interaction of CD95/FADD (Tauzin et al., 2012).  
Other mutations are reported on different website: 
COSMIC and LOVD. 
Germinal 
CD95 germinal mutations have been reported in 
ALPS type Ia. 
Somatic 




Hodgkin's lymphoma is a cancer of the immune 
system characterised by the presence of 
mononucleated Hodgkin's cells and multinucleated 
Reed-Sternberg cell. This disease can be caused by 
somatic mutation of CD95 (Tables 1 and 2). The 
symptoms are enlargement of lymph nodes, spleen 
or other immune tissue. Also non hodgkin's 
lymphoma (NHL) show somatic mutations of CD95 
(Tables 1 and 2): thyroid lymphoma, mucosa 
associated lymphoid tissue-type lymphomas, follicle 
center lymphomas, mycosis fungoide (cutaneous T 
cell lymphoma), nasal NK/T cell lymphoma, 
anaplastic large lymphoma, B-chronic lymphocytic 
lymphoma, and diffuse large B cells lymphomas. 8% 
of patients with NHL exhibits autoimmune 
phenomena (Grønbaek et al., 1995). 
Oncogenesis 
Table 2. Somatic mutations in the APT1 gene. * 
Amino acid numbers have been modified according 
to the regular amino acid annotation. ** Threonine 
256 depicted in this study corresponded in fact to 
amino acid 254. 
Various cancers 
Somatic mutations of CD95 have been also 
identified in various cancers (Table 2): multiple 
myelomas, T cell leukemia, cutaneous malignant 
melanoma, squamous cell carcinoma, bladder 
carcinoma, prostatic cancer, gastric cancer, testicular 
germ cell tumor, and non small cell lung cancer. 
Autoimmune lymphoproliferative 
syndrome type Ia 
ALPS is characterised by chronic lymphadenopathy 
and splenomegaly, expanded populations of double-
negative α/β T lymphocytes (CD3+, CD4-, CD8-). 
ALPS patients often develop autoimmunity. These 
patients exhibit germinal mutations in CD95 gene 
with no or rare "loss of heterozygosity" (Table 1). 
The ALPS patients show an increased risk to develop 
Hodgkin and non-Hodgkin lymphomas (Straus et al., 
2001). 
Systemic lupus erythematous 
Systemic lupus erythematous is a prototypic 
systemic autoimmune disorder characterized by 
autoantibody production, immune complex 
formation and cell-mediated reactivity against self. 
CD95/CD95L have been implicated in this disease. 
Breakpoints 
No translocation within the APT-1 gene have been 
identified. 
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